Suppression of postsurgical recurrence of hepatocellular carcinoma treated with autologous formalin-fixed tumor vaccine, with special reference to glypican-3

Autologous formalin-fixed tumor vaccine (AFTV) suppressed re-recurrence for more than 32 months of multiple-recurrent hepatocellular carcinoma based on hepatitis C virus-induced liver cirrhosis in a case with previous recurrence interval, 51-, 28-, 12-, and 4-months. We detected glypican-3-specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawashima, Issei, Kawashima, Yuri, Matsuoka, Yasuo, Fujise, Kiyotaka, Sakai, Hideki, Takahashi, Mari, Yoshikawa, Toshiaki, Nakatsura, Tetsuya, Ishihara, Takeshi, Ohno, Tadao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498860/
https://www.ncbi.nlm.nih.gov/pubmed/26185646
http://dx.doi.org/10.1002/ccr3.279
Descripción
Sumario:Autologous formalin-fixed tumor vaccine (AFTV) suppressed re-recurrence for more than 32 months of multiple-recurrent hepatocellular carcinoma based on hepatitis C virus-induced liver cirrhosis in a case with previous recurrence interval, 51-, 28-, 12-, and 4-months. We detected glypican-3-specific cytotoxic T lymphocytes in the peripheral blood at 12 months after AFTV.

Ejemplares similares